Interestingly, the use of the AR signalling inhibitors enzalutamide and abiraterone increased the number of non-neuroendocrine tumours that are independent of AR pathway activity to more than 20% of CRPC patients23. The gene discussed is AR; the disease is neuroendocrine neoplasm.